Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease

Table 3 Kidney Outcomes from the Semaglutide Cardiovascular Outcomes Trial (oral semaglutide in type 2 diabetes with cardiovascular or kidney disease)

Feature	Description	Oral semaglutide	Placebo	Hazard ratio (95%CI)
Major inclusion criteria	Adults ≥ 50 years with T2D and at least one of: CAD, cerebrovascular disease, symptomatic PAD, or- CKD (eGFR < 60 mL/min/1.73 m2)	-	-	-
5-point kidney composite outcome	Includes: CV death, kidney death, ≥ 50% eGFR decline, sustained eGFR < 15, or initiation of dialysis/transplant	10.4% (n = 502)	11.2% (n = 539)	0.91 (95%CI: 0.80-1.05)
4-point kidney outcome (excl. CV death)	Includes: Kidney death, ≥ 50% eGFR decline, sustained eGFR < 15, or dialysis/transplant	4.5% (n = 207)	5.2% (n = 251)	0.82 (95%CI: 0.68-0.98)
Kidney-related death	Death adjudicated as kidney-related	0.3% (n = 12)	0.3% (n = 13)	0.92 (95%CI: 0.42-2.00)
eGFR loss	Annual change in eGFR (mL/minute/1.73 m2)	-2.06	-1.67	ETD: 0.40 (95%CI: 0.27-0.53, P < 0.0001)

CV: Cardiovascular; eGFR: Estimated glomerular filtration rate; T2D: Type 2 diabetes; CKD: Chronic kidney disease; CAD: Coronary artery disease; ETD: Estimated treatment difference; PAD: Peripheral artery disease.